Plain-English translation of NCT06332430 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called , which is injected directly into tumors to help fight cancer. Researchers want to find out if the medication is safe, how well it works, and how it affects the immune system. The trial will enroll about 27 people with advanced solid tumors or lymphoma.
Many people with advanced cancers run out of effective treatment options because their tumors stop responding to standard therapies. This trial explores whether injecting medication directly into tumors might be a promising new way to treat these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the new medication directly into your tumor every three weeks. Researchers will monitor you closely with blood tests, imaging scans, and check-ins to watch for side effects and measure how your tumor responds. The trial will also track how the medication affects your immune system both at the injection site and throughout your body.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Canwell Biotech Limited
Enrollment target
~27 participants
Started
May 2024
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Herui Yao, MD
Canwell Biotech Limited
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.